Abstract Details

Title The use of the Traffic Light of Migraine Action Plan (TRALI-MAP) in Acute Migraine Treatment

Topic Headache

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-010

Objective

Primary Objective:
Quantitatively examine the effectiveness of TRALI-MAP using the Migraine Treatment Optimization Questionnaire (mTOQ-4).

Secondary Objectives:
Assess the impact of TRALI-MAP using the Migraine Disability Assessment Scale (MIDAS) and Patient Global Impression of Change (PGIC).

Quantitatively evaluate the ease of use and satisfaction in using TRALI-MAP using a modified validated questionnaire.

Background Early treatment is critical to minimize a patient’s headache and associated symptoms, but current migraine management tools assess headache pain, not associated disability in a patient-centered manner. The traffic light of migraine action plan (TRALI-MAP) is a novel stratified care strategy developed to close this gap in acute migraine management. This simple tool guides patients to help decide which of the acute treatment options to use based on the severity of their symptoms and the level of disability during a migraine attack.

Design/Methods A prospective single-center before-after interventional study was conducted at Women’s College Hospital in Toronto, Canada, to evaluate the acceptability of TRALI-MAP to guide acute treatment of migraine and assess migraine associated disability. We evaluated the usability of TRALI-MAP at their baseline visit, via phone call 4-weeks after initial visit, and at the 1^st follow-up visit (generally 2-3 months; phone call or in-person).

Results Twenty-eight patients diagnosed with episodic migraine without aura were contacted for recruitment, of whom 20 (71.4%) completed assessments. Mean age 35 years (range: 19-65 years), 90% women and 15% were also diagnosed with medication overuse headache. Overall, participants rated the usability (85%), satisfaction (80%), and usefulness (90%) of the TRALI-MAP positively. Compared to the baseline (55%), the treatment optimization, measured as moderate or maximal response to acute treatment, at the follow-up visit was 100%.

Conclusions

TRALI-MAP is an acceptable and useful tool in optimizing acute migraine treatment in migraine patients and offers a tool to assess the associated disability of an attack beyond headache.

Authors/Disclosures
James Im, MD (University of Toronto) PRESENTER	Dr. Im has nothing to disclose.
Ana-Marisa Lagman-Bartolome, MD (Hospital for Sick Children)	Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Searchlight. Dr. Lagman-Bartolome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Lagman-Bartolome has received research support from AMGEN. The institution of Dr. Lagman-Bartolome has received research support from Abbvie. The institution of Dr. Lagman-Bartolome has received research support from Lundbeck. Dr. Lagman-Bartolome has received publishing royalties from a publication relating to health care.
Manav Vyas, MD (MV VYAS MEDICINE PROFESSIONAL CORPORATION)	The institution of Dr. Vyas has received research support from Heart and Stroke Foundation of Canada . The institution of Dr. Vyas has received research support from Canadian Institutes of Health Research . Dr. Vyas has received research support from Heart and Stroke Foundation of Canada .
Ian Stanaitis, BMSc	Mr. Stanaitis has nothing to disclose.
Christine L. Lay, MD, FRCP (Women's College Hospital)	Dr. Lay has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Dr. Lay has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. The institution of Dr. Lay has received research support from Teva. The institution of Dr. Lay has received research support from Lundbeck.

��ɫ��

��ɫ��